A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study

Gavilá, J. ; De La Haba, J. ; Bermejo, B. ; Rodríguez-Lescure, Á. ; Antón, A. (Universidad de Zaragoza) ; Ciruelos, E. ; Brunet, J. ; Muñoz-Couselo, E. ; Santisteban, M. ; Rodríguez Sánchez, C.A. ; Santaballa, A. ; Sánchez Rovira, P. ; García Sáenz, J. Á. ; Ruiz-Borrego, M. ; Guerrero-Zotano, A.L. ; Huerta, M. ; Cotes-Sanchís, A. ; Lao Romera, J. ; Aguirre, E. ; Cortés, J. ; Llombart-Cussac, A.

Resumen: Purpose: To evaluate the efficacy and safety of lapatinib (L) and trastuzumab (T) combination in HER2-positive metastatic breast cancer (MBC) patients previously treated with T and/or L. Materials and methods: We conducted a retrospective, post-authorized, multicenter study including patients with HER2-positive MBC or locally advanced breast cancer (ABC) treated with the combination of L–T. Concomitant endocrine therapy, as well as brain metastasis and/or prior exposure to L, were allowed. Results: One hundred and fifteen patients from 14 institutions were included. The median age was 59.8 years. The median number of prior T regimens in the advanced setting was 3 and 73 patients had received a prior L regimen. The clinical benefit rate (CBR) was 34.8% (95% CI 26.1–43.5). Among other efficacy endpoints, the overall response rate was 21.7%, and median progression-free survival (PFS) and overall survival were 3.9 and 21.6 months, respectively. Heavily pretreated and ≥ 3 metastatic organ patients showed lower CBR and PFS than patients with a low number of previous regimens and < 3 metastatic organs. Moreover, CBR did not significantly change in L-pretreated compared with L-naïve patients (31.5% versus 40.5% for L-pretreated versus L-naïve). Grade 3/4 adverse events were reported in 19 patients (16.5%). Conclusion: The combination of L–T is an effective and well-tolerated regimen in heavily pretreated patients and remains active among patients progressing on prior L-based therapy. Our study suggests that the L–T regimen is a safe and active chemotherapy-free option for MBC patients previously treated with T and/or L.

Idioma: Inglés

DOI: 10.1007/s12094-019-02145-4

Año: 2020

Publicado en: Clinical and Translational Oncology 22 (2020), 420-428
ISSN: 1699-048X

Factor impacto JCR: 3.405 (2020)

Categ. JCR: ONCOLOGY rank: 159 / 241 = 0.66 (2020) - Q3 - T2

Factor impacto SCIMAGO: 0.902 - Cancer Research (Q2) - Oncology (Q2) - Medicine (miscellaneous) (Q2)

Tipo y forma: Artículo (PostPrint)

Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)